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Abstract 
During viral replication, the innate immune response is induced through the recognition 
of viral replication intermediates by host factor(s). One of these host factors, cyclic 
GMP-AMP synthetase (cGAS), was recently reported to be involved in the recognition 
of viral DNA derived from DNA viruses. However, it is uncertain whether cGAS is 
involved in the recognition of hepatitis B virus (HBV), which is a hepatotropic DNA 
virus. In the present study, we demonstrated that HBV genome-derived dsDNA induced 
the innate immune response through cGAS and its adaptor protein, STING, in human 
hepatoma Li23 cells expressing high levels of cGAS. In addition, we demonstrated that 
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HBV infection induced ISG56 through the cGAS-STING signaling pathway. This 
signaling pathway also showed an antiviral response towards HBV through the 
suppression of viral assembly. From these results, we conclude that the cGAS-STING 
signaling pathway is required for not only the innate immune response against HBV but 
also the suppression of HBV assembly. The cGAS-STING signaling pathway may thus 
be a novel target for anti-HBV strategies. 
 
Introduction 
Hepatitis B virus (HBV) is an enveloped double-stranded DNA (dsDNA) (3.2 kilobase; 
kb) virus classified into the Hepadnaviridae family. Chronic hepatitis is caused not only 
by hepatitis C virus (HCV) but also by HBV, and then progresses to liver cirrhosis and 
hepatocellular carcinoma. Since approximately 350 million people are infected with 
HBV worldwide, HBV infection is a serious global health problem [1, 2]. These 
diseases are tightly associated with inflammation caused by persistent HBV infection in 
the liver. To suppress the progression of hepatic diseases, it is necessary to prevent 
persistent HBV infection. However, HBV is known to evade the host innate immune 
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response for persistent infection [3, 4].  
   HBV has a relaxed circular DNA (rcDNA) as a viral genome [5, 6]. Following the 
invasion of HBV to hepatocytes, intracellular HBV rcDNA is converted to a covalently 
closed circular DNA (cccDNA) by DNA repair machinery. The transcription from the 
cccDNA is controlled by liver-enriched transcriptional factors [7, 8]. Four viral 
single-stranded RNAs (ssRNAs; 3.5, 2.4, 2.1, and 0.7 kb) are transcribed from HBV 
cccDNA. Among these viral ssRNAs, 3.5 kb RNA functions as an HBV pregenomic 
RNA (pgRNA). By the reverse transcriptase activity of HBV DNA polymerase, a 
negative-stranded DNA is synthesized from HBV pgRNA, and subsequently HBV 
rcDNA is formed by the synthesis of positive-stranded DNA from negative-stranded 
DNA. HBV rcDNA contains four open-reading frames (ORFs) encoding preS1/preS2/S 
(S), precore/core (C), polymerase (P), and X antigen genes (known as S gene, C gene, P 
gene, and X gene, respectively). S gene encodes three envelop proteins of different 
sizes; Large S (prepreS1/preS2/S), Middle S (preS2/S), and Small S (S), respectively. P 
gene encodes DNA polymerase responsible for the reverse transcription of HBV 
pgRNA [5, 6].  
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   During the life cycle of HBV, viral dsDNA (rcDNA and cccDNA), viral 
single-stranded DNA (ssDNA; positive or negative strand) and four viral ssRNAs are 
produced as viral replication intermediates. Since HBV replication contains the step of 
reverse transcription, it has been predicted that a DNA:RNA duplex is produced as a 
viral replication intermediate [5]. Very recently, the RNA sensor RIG-I was reported to 
induce the innate immune response through recognition of the 5’-εregion of HBV 
pgRNA [9]. However, the host recognition mechanism toward HBV DNA remains 
unclear. One of the DNA sensors, cyclic GMP-AMP synthetase (cGAS), was recently 
reported to recognize cytosolic DNA, and to induce the activation of transcription factor 
IRF-3 and subsequently the production of interferon (IFN)-β  and numerous 
IFN-stimulated genes (ISGs) such as ISG56 (also known as IFIT1) and ISG15 in a 
STING (adaptor protein of cGAS)-dependent manner (this sequence is known as the 
cGAS-STING signaling pathway) [10]. The cGAS-STING signaling pathway was also 
required for the recognition of infection with several viruses such as herpes simplex 
virus type 1 (HSV-1) [11], vaccinia virus (VACV) [11], and human immunodeficiency 
virus (HIV) [12]. Therefore, we presumed that the cGAS-STING signaling pathway is 
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involved in the recognition of HBV infection. To evaluate this presumption, we 
examined whether the cGAS-STING signaling pathway is required for the recognition 
of HBV using human hepatoma Li23 cells [13] and HBV-replicating HepG2.2.15 cells 
[14]. 
   Here, we show that the cGAS-STING signaling pathway is required for the innate 
immune response against HBV, and that this signaling pathway is also involved in the 
suppression of HBV assembly. 
 
Results 
The synthetic analogues of Z-form DNA, p-dGdC, induced ISG56 in Li23 cells 
 
Host cells induce the innate immune response through the recognition of viral 
replication intermediates. Very recently, the RNA sensor, RIG-I, was reported to 
recognize the 5’- region of HBV pgRNA [9]. However, the host recognition 
mechanism toward HBV DNA is uncertain. To clarify this mechanism, hepatic cell lines 
showing an innate immune response to HBV DNA were required. Therefore, we first 
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evaluated the capabilities of synthetic DNA or RNA analogues such as poly dAdT 
(p-dAdT; as B-form DNA), poly dGdC (p-dGdC; as Z-form DNA), poly IC (p-IC; as 
double-stranded RNA: dsRNA), 5’-ppp dsRNA, and poly AdT (p-AdT; as DNA:RNA 
duplex) as indices of ISG56 induction [15]. Having checked several human hepatic cell 
lines, we found that only Li23 (human hepatoma cell line) and NKNT-3 (human 
immortalized hepatocyte cell line) showed the innate immune responses to both p-dGdC 
and p-dAdT (Table 1). These findings also suggest that the mechanism of recognition to 
p-dGdC (Z-form DNA) is distinct from that to p-dAdT (B-form DNA), and that the host 
factor or factors involved in the recognition of p-dGdC is or are expressed only in Li23 
and NKNT-3 cells. Since Li23 cells have been well genetically characterized [13, 
16-18], we used the Li23 cell line in the following study. 
 
P-dGdC triggered the cGAS-STING signaling pathway in Li23 cells 
 
We next tried to identify the host factor(s) required for the recognition of p-dGdC in 
Li23 cells. HCV nonstructural protein 3 and 4A (NS3/4A) are known to prevent the 
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RIG-I/IPS-1-mediated signaling pathway through the cleavage of IPS-1 [19, 20]. 
Therefore, using Li23 cells stably expressing exogenous HCV NS3/4A (designated Li23 
NS3/4A cells), we examined whether p-dGdC and p-dAdT induced ISG56 through the 
RIG-I/IPS-1-mediated signaling pathway. The results revealed that NS3/4A did not 
prevent ISG56 induction by p-dAdT, although that by p-IC was absolutely prevented by 
NS3/4A (left and central panels in Fig. 1A). NS3/4A also did not inhibit ISG56 
induction by p-dGdC (right panel in Fig. 1A). These results suggest that the 
dsDNA-triggered signaling pathway is distinct from the RIG-I/IPS-1-mediated 
signaling pathway in Li23 cells.  
   On the other hand, it was reported that cytosolic DNA was recognized by cGAS and 
subsequently induced the innate immune response [10-12]. Therefore, we examined the 
expression levels of cGAS in several human hepatic cell lines, including Li23. We 
obtained the interesting result that cGAS mRNA was highly expressed in only NKNT-3 
and Li23 cells (Fig. 1B). This result is in accord with the former result that only 
NKNT-3 and Li23 cells were able to recognize p-dGdC (Table 1). Therefore, we next 
examined whether cGAS is required for the p-dGdC-triggered signaling pathway. The 
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results revealed that p-dGdC-triggered ISG56 induction was remarkably prevented in 
cGAS-knockdown Li23 cells (Fig. 1C and right panel in Fig. 1D). Since p-dAdT, but 
not p-IC-triggered ISG56 induction was also significantly prevented in the 
cGAS-knockdown cells (central and left panels in Fig. 1D), we inferred that the 
p-dAdT-triggered signaling pathway was also partially regulated by cGAS in Li23 cells.  
   It has been also reported that cGAS activates its downstream transcription factor, 
IRF-3, and subsequently induces IFN-β and ISGs through the association with its 
adaptor protein, STING [10]. Therefore, we examined whether STING and IRF-3 were 
required for the p-dGdC- or p-dAdT-triggered signaling pathway in Li23 cells. The 
results revealed that STING- (Fig. 2A) and IRF-3-knockdown (Fig. 2B) Li23 cells 
greatly weakened both p-dGdC- and p-dAdT-triggered ISG56 induction (Figs. 2C and 
2D). Taken together, these results lead us to suggest that the cGAS-STING signaling 
pathway is required for the recognition of p-dGdC, and that this pathway is partially 
involved in the recognition of p-dAdT. 
 
HBV triggered the cGAS-STING signaling pathway 
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It has been reported that the cGAS-STING signaling pathway functions as an antiviral 
sensor for infection with DNA viruses such as HSV-1 and VACV [11]. Therefore, we 
used several synthetic dsDNAs, including HBV-derived dsDNA, to examine whether 
the cGAS-STING signaling pathway is required for the recognition of HBV dsDNA 
(Fig. 3A). Although ISG56 was reproducibly induced by HBV-derived synthetic dsDNA 
as well as p-dGdC and VACV- or HSV-derived dsDNA, these inductions were 
remarkably prevented in the cGAS-knockdown (left panel of Fig. 3B) and 
STING-knockdown (right panel of Fig. 3B) Li23 cells. In addition, HBV positive- and 
negative-stranded ssDNA did not induce ISG56 in Li23 cells (Fig. 3C). These results 
suggest that the cGAS-STING signaling pathway is required for the recognition of HBV 
dsDNA. 
   It is important to examine whether the cGAS-STING pathway functions as a sensor 
for viral dsDNA occurring in HBV-reproducing cells. HBV-replicating HepG2.2.15 
cells are currently used for the study of the life cycle of HBV worldwide [14]. Since 
both HepG2.2.15 cells and their parental HepG2 cells exhibit defective cGAS 
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expression and low STING expression compared with those in Li23 cells (Fig. 4A), we 
first prepared HepG2 and HepG2.2.15 cells stably expressing both exogenous cGAS or 
cGAS GSAA (the inactive mutant of cGAS), and STING (designated HepG2 
cGAS/STING, HepG2 cGAS GSAA)/STING, HepG2.2.15 cGAS/STING, and 
HepG2.2.15 cGAS GSAA)/STING cells) (Fig. 4B). The results showed that ISG56 (Fig. 
4C) and ISG15 (Fig. 4D) were induced only in HepG2.2.15 cGAS/STING cells.  
   We next examined whether the cGAS-STING pathway functions as a sensor for 
viral dsDNA occurring in HBV-infecting cells. The sodium taurocholate cotransporting 
polypeptide (NTCP) was recently shown to act as a functional receptor for HBV [21]. 
Since HepG2 cells showed defective NTCP expression, we prepared HepG2/NTCP-myc 
cells stably expressing both exogenous cGAS or cGAS GSAA, and STING in addition 
to NTCP containing myc tag (designated HepG2/NTCP-myc cGAS/STING and 
HepG2/NTCP-myc cGAS GSAA/STING cells) for an experiment on HBV infection. 
We also prepared an HBV inoculum by concentrating the supernatant of HepG2.2.15 
cells (designated HBVcc; cell-cultured HBV). At 13 days after HBVcc infection, we 
observed that ISG56 was induced in HepG2/NTCP-myc cGAS/STING cells, but not in 
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HepG2/NTCP-myc cGAS GSAA/STING cells (Fig. 4E). These results suggest that 
HBV triggered the cGAS-STING signaling pathway. 
 
The cGAS-STING signaling pathway showed an antiviral response towards HBV 
through the suppression of viral assembly 
 
To evaluate the antiviral response toward HBV through the cGAS-STING pathway, we 
first examined the level of HBV RNA in HepG2.2.15 cGAS/STING cells. Northern blot 
analysis revealed that the 3.5 kb HBV RNA (corresponding to HBV pgRNA) was 
slightly reduced in HepG2.2.15 cGAS/STING cells compared with the level in control 
cells (Fig. 5A). Quantitative analysis also revealed that the levels of HBV total 
transcript and pgRNA were significantly reduced in HepG2.2.15 cGAS/STING cells, 
compared with the control cells. Such a reduction was not observed in HepG2.2.15 
cGAS GSAA/STING cells (Fig. 5B). We further examined the levels of HBV RNA after 
HBVcc infection. At 13 days after infection, we again observed that the total amount of 
HBV transcript was significantly reduced only in HepG2/NTCP-myc cGAS/STING 
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cells, compared with the control cells or HepG2/NTCP-myc cGAS GSAA/STING cells 
(Fig. 5C). 
   We next carried out Southern blotting and its quantitative analysis to examine the 
level of HBV DNA in HepG2.2.15 cGAS/STING cells. The results showed that the 
level of intracellular HBV DNA was not reduced in HepG2.2.15 cGAS/STING cells, 
compared with the control cells (Fig. 6A and the left panel of Fig. 6B). However, we 
found that the infectivity of intracellular HBVcc was significantly reduced in 
HepG2.2.15 cGAS/STING cells, compared with the control cells or HepG2.2.15 cGAS 
GSAA/STING cells (the right panel of Fig. 6B). Moreover, we found that the 
extracellular HBV DNA and the infectivity of extracellular HBVcc were reduced only 
in HepG2.2.15 cGAS/STING cells (Fig. 6C). From these results, we conclude that the 
cGAS-STING signaling pathway negatively regulates the viral assembly.  
 
Low expression of endogenous cGAS in Li23 cells increased the permissiveness to 
HBV infection 
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Our findings that HBV triggered an antiviral response through the cGAS-STING 
signaling pathway suggested that the expression level of endogenous cGAS might affect 
the permissiveness to HBV infection. To investigate this possibility, we first prepared 
Li23/NTCP-myc cells stably expressing NTCP containing a myc tag, and then 
established dozens of subcloned cell lines by the limited dilution of Li23/NTCP-myc 
cells to obtain cell lines showing different levels of cGAS expression. Among the 
obtained cell lines, we selected A7 cells, which showed the highest level of cGAS 
expression, and A8 cells, which showed the lowest level of cGAS expression (Fig. 7A). 
An HBV infection experiment using A7 and A8 cells in addition to parental 
Li23/NTCP-myc cells revealed that the permissiveness to HBV infection in A7 cells 
was lower than that in the parental cells and the permissiveness in A8 cells was higher 
than that in the parental cells (Fig. 7B). At 13 days after HBVcc infection, we also 
observed that ISG56 was induced in A7 cells, but not in A8 cells (Fig. 7C). In addition, 
we observed that B34 and B48 subcloned cells, which showed a low level of cGAS 
expression equivalent to that in A8 cells (Fig. S1A), also showed higher permissiveness 
to HBV infection than that in the parental cells (Fig. S1B). These results also suggest 
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that cGAS is a host factor which may regulate the permissiveness to HBV infection. 
 
Discussion 
 
The DNA double helix is known to form a right-handed conformation (i.e., A-form or 
B-form DNA) or left-handed conformation (i.e., Z-form DNA). Most DNA exists as the 
B-form in vitro and in vivo. B-form DNA such as p-dAdT is recognized by DDX41 in 
myeloid dendritic cells [22] (Fig. 7C). Interestingly, under certain conditions, DNA is 
reported to transit from B-form to Z-form. As the case in vitro, it was previously 
reported that the insertion of the sequence (dC-dG)n into plasmid DNA pBR322 
promoted the transition from B-form DNA to Z-form DNA in their negatively 
supercoiled cccDNA [23-25]. On the other hand, the antibodies specific to Z-form DNA 
were previously shown to be present in the sera of patients with systemic lupus 
erythematosus [26]. This result implies that Z-form DNA may be recognized in host 
cells as “non-self” DNA, although the biological functions of Z-form DNA have 
remained uncertain. In the present study, using Li23 cells expressing cGAS, we 
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demonstrated that the cGAS-STING signaling pathway was required for the recognition 
of the synthetic p-dGdC (Z-form), HBV, HSV-1- or VACV-derived dsDNA (Fig. 3B). In 
contrast, in PH5CH8 cells, which do not express cGAS, only p-dAdT (B-form DNA) 
induced the innate immune response, and p-dGdC (Table 1), HBV-, HSV-1- or VACV- 
derived dsDNA (data not shown) was not absolutely recognized. These results suggest 
that the synthetic HBV-derived dsDNA as well as HSV-1- or VACV-derived dsDNA 
takes the conformation of Z-form in the cells. According to other groups, the 
cGAS-STING signaling pathway was required for the recognition of several viruses, 
such as HSV-1 [11], VACV [11], and HIV [12]. We also demonstrated that the 
cGAS-STING signaling pathway was required for the recognition of HBV dsDNA, and 
functioned as an antiviral mechanism through the induction of ISG56 (Figs. 4C and 4E). 
These results imply that cGAS may play an important role in the recognition of Z-form 
DNA, such as viral replication intermediates produced from DNA virus as “non-self” 
DNA (Fig. 7D). 
   The cGAS-STING signaling pathway also suppressed the infectivity of intracellular 
HBV without a reduction of intracellular HBV DNA (Fig. 6B). This result suggests that 
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the cGAS-STING signaling pathway may negatively regulate the viral assembly. The 
5’-cap structure of HBV pgRNA is essential for viral encapsidation [27]. On the other 
hand, ISG56 is known to inhibit the replication of some viruses by inhibiting viral 
translation through binding to the 5’-cap structure of viral RNA [15]. Further analysis is 
needed to clarify whether the cGAS-STING signaling pathway inhibits viral 
encapsidation or viral translation through the binding of ISG56 to the 5’-cap structure of 
HBV pgRNA. 
   Recently it was reported that both HBV and HCV were able to replicate and 
proliferate in a newly developed hepatoma cell line, HLCZ01 [28]. This result implies 
that the common important host factor or factors for the complete life cycles of both 
HBV and HCV are present in hepatocyte. We previously found that human hepatoma 
HuH-7-derived RSc cells and Li23-derived ORL8c cells showed higher permissiveness 
of HCV than their parental HuH-7 and Li23 cells, respectively [13, 29]. In the present 
study, we demonstrated that the high permissiveness to HBV infection was related to 
lower cGAS expression using several cell lines subcloned from Li23/NTCP-myc cells 
(Figs. 7A and 7B, and Fig. S1). In this context, interestingly, Li23-derived ORL8c cells 
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showed defective expression of cGAS and showed no responsiveness to p-dGdC (data 
not shown). From these results, it is predicted that ORL8c cells possess an environment 
that is advantageous to HBV multiplication. ORL8c may be a useful cell line for the 
development of both HBV and HCV-replicating cells. 
 
Experimental procedures 
 
Cell cultures and reagents 
 
Human hepatoma Li23 cells [13] were cultured in modified medium for human 
immortalized hepatocyte PH5CH8 cells [30] as previously described [13]. Other human 
immortalized hepatocytes, NKNT-3 [31] and OUMS-29 cells [32], which were kindly 
provided by Drs. Noriyuki Kobayashi and Masayoshi Namba (Okayama University), 
were also maintained in this modified medium for human immortalized hepatocytes. 
Human hepatoma HuH-7, PLC/PRF/5, HT17, HLE, and HepG2 cells were cultured in 
Dulbecco’s modified Eagle’s medium (Invitrogen, Carlsbad, CA, USA) supplemented 
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with 10% fetal bovine serum as previously described [16, 18]. Li23 NS3/4A cells were 
maintained in medium including blasticidin as previously described [19, 33]. 
HepG2.2.15 cells [14] were kindly provided by Dr. Takaji Wakita (National Institute of 
Infectious Disease, Tokyo, Japan). 
   HepG2/NTCP-myc cells and Li23/NTCP-myc cells were prepared by the retroviral 
transfer of myc-tagged NTCP. Limited dilution of Li23/NTCP-myc cells were 
performed to establish the subcloned cell lines.  
   In vitro synthesized ligands such as p-IC, 5’-ppp dsRNA, p-dGdC, and p-dAdT 
were purchased from InvivoGen (San Diego, CA, USA). Synthetic dsDNA derived 
from HSV-1 and VACV were also purchased from InvivoGen. In vitro synthesized 
p-AdT was purchased from The Midland Certified Reagent Company (Midland, TX, 
USA). 
 
Quantitative RT-PCR analysis 
 
In vitro synthesized ligands were complexed with Lipofectamine 2000 (Invitrogen) for 
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the transfection as previously described [19]. Total cellular RNA was isolated from the 
cells at 6 h after transfection by using an RNeasy Mini Kit (Qiagen, Hilden, Germany). 
RT was performed as previously described [33]. For quantitative PCR, we used a SYBR 
Premix Ex Taq Kit (TaKaRa Bio, Otsu, Japan) and the following primer sets: for ISG56 
[34], IRF-3 [19], and GAPDH [35]. We also prepared the following forward and reverse 
primer sets for cGAS, 5’-AAGCTCCGGGCGGTTTTGGA-3’ (forward) and 
5’-AGGTGCAGAAATCTTCACGTGCTC-3’ (reverse); for STING, 
5’-GTGGCTTGAGGGGAACCCGC-3’ (forward) and 
5’-GGCTGGAGTGGGGCATCTTCT-3’ (reverse). These expression levels were 
normalized to the levels of GAPDH mRNA. We used total RNA isolated from the cells 
without the transfection of ligand as a control; (-). Data are the means ± SD from three 
independent experiments.  
 
RNA interference 
 
Small interfering RNAs (siRNAs) targeting cGAS (Thermo Fisher Scientific, Waltham, 
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MA; M-015607-01-0005), STING (M-024333-00-0005), IRF-3 (M-006875-01-0005), 
or nontargeting siRNAs (D-001206-13-20) were introduced into Li23 cells by 
DharmaFECT transfection reagent (Thermo Fisher Scientific). The effects of siRNAs 
were confirmed by the quantitative RT-PCR and Western blot analysis using anti-cGAS 
(Cell Signaling Technology, Beverly, MA, USA), anti-STING (Cell Signaling 
Technology) and anti-IRF-3 (Santa Cruz Biotechnology, Santa Cruz, CA) antibodies. At 
3 days after the introduction of siRNAs, the knockdown cells were transfected with 
several ligands. 
 
Synthetic HBV dsDNA 
 
Two oligonucleotides (nt 1750-1795 according to C_JPNAT clone with accession no. 
AB246345) [36] derived from the positive- or negative-stranded HBV DNA were 
synthesized in vitro. These oligonucleotides were annealed by heating at 70 degrees for 
10 minutes followed by slow cooling to room temperature. The annealed product was 
confirmed by agarose gel electrophoresis. 
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Generation of cells stably expressing exogenous cGAS or STING 
 
To construct pCX4bsr/HA-cGAS and pCX4pur/Myc-STING retroviral vectors, we 
introduced cGAS (accession no. NM_138441) and STING (accession no. NM_198282) 
cDNA containing a full-length ORF into the pCX4bsr/HA or pCX4pur/Myc retroviral 
vector, respectively, as previously reported [37]. These vectors were simultaneously 
introduced into HepG2.2.15 cells, HepG2 cells or HepG2/NTCP-myc cells by the 
retroviral transfer and subsequently selected the cells stably expressing exogenous 
cGAS and STING by blasticidin and puromycin. We also introduced both pCX4bsr and 
pCX4pur vectors into cells as control cells. At 3 days after transfection, total cellular 
RNA, and the cell lysate were prepared from both these cells. The exogenous 
expression of cGAS and STING were confirmed by the quantitative RT-PCR or Western 
blot analysis using anti-HA (Cell Signaling Technology, Beverly, MA, USA) antibodies 
as previously described [34].  
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HBV infection 
 
HBVcc was prepared from the supernatant of HepG2.2.15 cells. The supernatant was 
concentrated by the addition of one-fourth volume of 40% (w/v) polyethylene glycol 
(PEG) 8000 in PBS (final 8% (w/v)) followed by incubation at 4 degrees overnight. The 
precipitates, HBVcc, were collected by centrifugation and then used as the HBV 
inoculum. Inoculation using HBVcc was performed with 1000 HBV genome 
equivalents per cell in culture medium containing 4% PEG 8000 and 2% DMSO for 24 
hr. At 24 hr after the inoculation, the culture medium was replaced with fresh medium. 
 
Analysis of HBV DNA 
 
For analysis of the intracellular HBV DNA, total cellular DNA was isolated by 
UltraPure Phenol: Chloroform: Isoamyl Alcohol (25: 24: 1, v/v) (Invitrogen), and was 
subjected to Southern blot analysis. Briefly, total cellular DNA was separated on 0.8% 
agarose gel and then transferred to a Hybond-N+ membrane (GE Healthcare) using a 
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standard neutral transfer procedure. To prepare the DIG-labeled HBV minus-stranded 
specific riboprobe, we constructed pTZ19R 1403-2907AS by introducing the antisense 
strand of the HBV DNA fragment (nts 1403-2907 according to the D_IND60 clone with 
accession no. AB246347, [36]) into pTZ19R. pTZ19R 1403-2907AS was linearized by 
EcoRI to provide a template for synthesis of the DIG-labeled HBV minus-stranded 
specific riboprobe using a T7 Megascript kit (Ambion, Austin, TX) and DIG RNA 
labeling mix (Roche). The transferred membrane was hybridized with the DIG-labeled 
HBV minus-stranded specific riboprobe, and then HBV DNA was detected using 
anti-DIG antibody (Roche).  
   For analysis of the extracellular HBV DNA and viral infectivity, the supernatants of 
HepG2-derived cells were collected. Extracellular DNA was isolated from the 
supernatant by using a DNeasy Blood & Tissue Kit (Qiagen). Quantitative PCR analysis 
of HBV DNA was performed as previously reported [21]. pC_JPNAT plasmid DNA 
[36] was used as a standard to calculate the amount of HBV DNA. Data are the means ± 
SD from three independent experiments.  
   The supernatant of HepG2-derived cells was also used for the inoculation to 
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HepG2/NTCPmyc cells in culture medium containing 4% PEG 8000 and 2% DMSO. 
At 4 days after the inoculation, total RNA was isolated by using an RNeasy Mini Kit 
(Qiagen). Quantitative RT-PCR analysis of HBV RNA was performed to evaluate the 
viral infectivity of the supernatant as described below. 
 
Analysis of HBV RNA 
 
For the analysis of the intracellular HBV RNA, total RNA was isolated by using an 
RNeasy Mini Kit (Qiagen), and was subjected to Northern blot analysis. Total RNA was 
separated on 0.8% agarose gel and then transferred to a Hybond-N+ membrane (GE 
Healthcare) using a standard transfer procedure. DIG-labeled HBV plus-stranded 
specific riboprobe was prepared from pTZ19R 1426-1896 (corresponding to the sense 
strand of HBV DNA; nts 1426-1896 of the D_IND60 clone) using a T7 Megascript kit 
(Ambion, Austin, TX) and DIG RNA labeling mix (Roche). The transferred membrane 
was hybridized with the DIG-labeled HBV plus-stranded specific riboprobe, and then 
HBV RNA was detected using anti-DIG antibody (Roche).  
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   Quantitative RT-PCR analysis of HBV RNA was performed as previously reported 
[21]. pC_JPNAT plasmid DNA [36] was used as a standard to calculate the amount of 
HBV RNA. Data are the means ± SD from three independent experiments.  
 
Statistical analysis 
 
The significance of differences among groups was determined using Student’s t-test. 
P<0.05 was considered statistically significant. 
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Table 1 
Responsibility against ligands in various human hepatocyte cells 
Ligand 
 dsRNA dsDNA RNA:DNA duplex 
 p-IC 5’-ppp 
dsRNA
p-dGdC p-dAdT      p-AdT 
Human immortalized 
hepatocyte cell 
     
PH5CH8 1866  196    9  2147        5 
NKNT-3  206   41  396  1948        9 
OUMS29  481   85    8  2097        7 
Human hepatoma cell   
Li23 2109    7  102   655        3 
HuH-7 1281   13    7    34        5 
HepG2 6466   11    6  1140        5 
PLC/PRF/5  461   11    9    75        7 
HT17 1462    6   13   206        3 
HLE  224    9    9    55        5 
Quantitative RT-PCR analysis of ISG56 mRNA was performed. Each level of ISG56 mRNA 
level was calculated relative to the level in the cells without treatment of the ligand, which was 
set at 10.    
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Figure Legends  
 
Fig. 1. cGAS was required for the p-dGdC-triggered signaling pathway in Li23 cells. 
(A) Quantitative RT-PCR analysis of ISG56 mRNA in Li23 NS3/4A cells treated with 
p-IC (left panel), p-dAdT (central panel), or p-dGdC (right panel). The level of ISG56 
mRNA was calculated relative to the level in Li23 Cont cells without ligand treatment; 
(-), which was set at 1. (B) Quantitative RT-PCR analysis of cGAS mRNA in several 
human cell lines. Total RNA derived from human normal liver was used as the control. 
The level of cGAS mRNA was calculated relative to the level in Li23 cells, which was 
set at 100%. (C) (Left panel) Quantitative RT-PCR analysis of cGAS mRNA in Li23 
cells transfected with cGAS-specific (designated Li23 sicGAS) or control (designated 
Li23 siCont) siRNA. The level of cGAS mRNA was calculated relative to the level in 
Li23 siCont cells, which was assigned as 100%. (Right panel) Western blot analysis of 
cGAS, STING, and IRF-3 in Li23 sicGAS cells. -actin was included as a loading 
control. (D) (Upper panels) Quantitative RT-PCR analysis of ISG56 mRNA in Li23 
sicGAS cells treated with p-IC (left panel), p-dAdT (central panel) or p-dGdC (right 
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panel). The level of ISG56 mRNA was calculated relative to the level in Li23 siCont 
cells without ligand treatment; (-), which was set at 1. (Lower panels) Western blot 
analysis of ISG56 in Li23 sicGAS cells treated with p-IC (left panel), p-dAdT (central 
panel) or p-dGdC (right panel). 
 
Fig. 2. STING and IRF-3 were required for the p-dGdC-triggered signaling pathway in 
Li23 cells. (A) (Upper panel) Quantitative RT-PCR analysis of STING mRNA in Li23 
cells transfected with STING-specific (designated Li23 siSTING) or control (designated 
Li23 siCont) siRNA. The level of STING mRNA was calculated relative to the level in 
Li23 siCont cells, which was assigned as 100%. (Lower panel) Western blot analysis of 
STING in Li23 siSTING cells. (B) (Upper panel) Quantitative RT-PCR analysis of 
IRF-3 mRNA in Li23 cells transfected with IRF-3-specific (designated Li23 siIRF-3) or 
control (designated Li23 siCont) siRNA. The level of IRF-3 mRNA was calculated 
relative to the level in Li23 siCont cells, which was assigned as 100%. (Lower panel) 
Western blot analysis of IRF-3 in Li23 siIRF-3 cells. (C) (Upper panels) Quantitative 
RT-PCR analysis of ISG56 mRNA in Li23 siSTING cells treated with p-dGdC (left 
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panel) and p-dAdT (right panel). The level of ISG56 mRNA was calculated relative to 
the level in Li23 siCont cells without ligand treatment; (-), which was set at 1. (Lower 
panels) Western blot analysis of ISG56 in Li23 siSTING cells treated with p-dGdC (left 
panel) and p-dAdT (right panel). (D) (Upper panels) Quantitative RT-PCR analysis of 
ISG56 mRNA in Li23 siIRF-3 cells treated with p-dGdC (left panel) and p-dAdT (right 
panel). The level of ISG56 mRNA was calculated relative to the level in Li23 siCont 
cells without ligand treatment; (-), which was set at 1. (Lower panels) Western blot 
analysis of ISG56 in Li23 siIRF-3 cells treated with p-dGdC (left panel) and p-dAdT 
(right panel). 
 
Fig. 3. HBV-derived dsDNA was recognized through the cGAS-STING signaling 
pathway in Li23 cells. (A) Agarose gel electrophoresis of the synthesized HBV-derived 
dsDNA. P-dAdT, p-dGdC, VACV-derived dsDNA, and HSV-derived dsDNA were also 
loaded on agarose gel (2.0%) for reference. (B) Quantitative RT-PCR analysis of ISG56 
mRNA in Li23 sicGAS cells (left panel) or Li23 siSTING cells (right panel) treated 
with p-dGdC, HBV-, VACV-, or HSV-derived dsDNA. The level of ISG56 mRNA was 
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calculated relative to the level in Li23 siCont cells without ligand treatment; (-), which 
was set at 1. (C) Quantitative RT-PCR analysis of ISG56 mRNA in Li23 cells treated 
with HBV positive- or negative-stranded ssDNA (designated Pos or Neg, respectively). 
The level of ISG56 mRNA was calculated relative to the level in Li23 cells without 
ligand treatment (-), which was set at 1. 
 
Fig. 4. HBV triggered the cGAS-STING signaling pathway in HepG2.2.15 cells. (A) 
(Upper panels) Quantitative RT-PCR analysis of cGAS (left panel), STING (central 
panel), and IRF-3 (right panel) mRNAs in HepG2 cells or HepG2.2.15 cells. Each 
mRNA level was calculated relative to the level in Li23 cells, which was assigned a 
value of 100%. (Lower panel) Western blot analysis of cGAS in HepG2 cells or 
HepG2.2.15 cells. (B) Quantitative RT-PCR analysis of cGAS mRNAs in HepG2 
cGAS/STING cells or HepG2.2.15 cGAS/STING cells. HepG2 Cont cells, HepG2 
cGAS GSAA/STING cells, HepG2.2.15 Cont cells and HepG2.2.15 cGAS 
GSAA/STING cells were used as control cells. Each mRNA level was calculated 
relative to the level in HepG2 cGAS/STING cells, which was assigned a value of 100%. 
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(C) Quantitative RT-PCR analysis of ISG56 mRNAs in HepG2 cGAS/STING cells or 
HepG2.2.15 cGAS/STING cells. Control cells were used as described in Fig. 4B. Each 
mRNA level was calculated relative to the level in HepG2 Cont cells, which was set at 1. 
(D) Western blot analysis of ISG15 in HepG2 cGAS/STING cells or HepG2.2.15 
cGAS/STING cells. Control cells were used as described in Fig. 4B. β-actin was 
included as a loading control. (E) Quantitative RT-PCR analysis of ISG56 mRNAs in 
HBV-infected HepG2/NTCP-myc cGAS/STING cells. HepG2/NTCP-myc Cont cells 
and HepG2/NTCP-myc cGAS GSAA/STING cells were used as control cells. The 
supernatant of HepG2.2.15 was used as HBVcc. Each mRNA level was calculated 
relative to the level in mock-infected HepG2/NTCP-myc Cont cells, which was set at 1.  
 
Fig. 5. The cGAS-STING signaling pathway significantly reduced the levels of HBV 
RNA in HepG2.2.15 cells. (A) Northern blot analysis of the total amount of HBV 
transcript in HepG2.2.15 cGAS/STING cells. HepG2.2.15 Cont cells and HepG2.2.15 
cGAS GSAA/STING cells were used as control cells. β-actin was included as a 
loading control. (B) Quantitative RT-PCR analysis of the total HBV transcript and 
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pgRNA in HepG2.2.15 cGAS/STING cells. Control cells were used as described in Fig. 
5A. Total RNA extracted from the cells was subjected to quantitative RT-PCR analysis. 
(C) Quantitative RT-PCR analysis of the total HBV transcript in HBV-infected 
HepG2/NTCP-myc cGAS/STING cells. Control cells and HBVcc were used as 
described in Fig. 4E. Total RNA extracted from the cells was subjected to quantitative 
RT-PCR analysis.   
 
Fig. 6. The cGAS-STING signaling pathway showed an antiviral response towards 
HBV through the suppression of viral assembly. (A) Southern blot analysis of HBV 
DNA in HepG2.2.15 Cont, cGAS/STING, or cGAS GSAA/STING cells. M: 
genome-length HBV DNA (pC_JPNAT plasmid DNA cleaved by EcoRI and HindIII); 
RC: HBV relaxed circular DNA; SS: HBV ssDNA. (B) Quantitative PCR analysis of 
the total amount of HBV DNA in HepG2.2.15 Cont, cGAS/STING or cGAS 
GSAA/STING cells (left panel). Total cellular DNA extracted from the cells was 
subjected to quantitative PCR analysis. Quantitative RT-PCR analysis of the total HBV 
transcript in HepG2/NTCP-myc cells was performed at 5 days after infection with 
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intracellular HBV (right panel). The lysate was recovered as intracellular HBV from 
HepG2.2.15 Cont, cGAS/STING or cGAS GSAA/STING cells. Total RNA extracted 
from intracellular HBV-infected cells was subjected to quantitative RT-PCR analysis. 
(C) Quantitative PCR analysis of HBV total DNA in the supernatant released from 
HepG2.2.15 Cont, cGAS/STING, or cGAS GSAA/STING cells (left panel). Total DNA 
extracted from the supernatant was subjected to quantitative PCR analysis. Quantitative 
RT-PCR analysis of the total HBV transcript in HepG2/NTCP-myc cells at 5 days after 
infection with extracellular HBV (right panel). The supernatant was recovered as 
extracellular HBV from HepG2.2.15 Cont, cGAS/STING, or cGAS GSAA/STING cells. 
Total RNA extracted from extracellular HBV-infected cells was subjected to 
quantitative RT-PCR analysis.  
 
Fig. 7. The expression level of endogenous cGAS was inversely correlated with the 
permissiveness to HBV infection. (A) Quantitative RT-PCR analysis of cGAS mRNAs 
in Li23/NTCP-myc cells (Parent), and their subcloned A7, or A8 cells. Each mRNA 
level was calculated relative to the level in parental Li23/NTCP-myc cells, which was 
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assigned a value of 100%. (B) Quantitative RT-PCR analysis of the total amount of 
HBV transcript in HBV-infected Li23/NTCP-myc Parent, A7 or A8 cells. HBVcc were 
used as described in Fig. 4E. Total RNA extracted from the cells was subjected to 
quantitative RT-PCR analysis. ND, not determined. (C) Quantitative RT-PCR analysis 
of ISG56 mRNAs in HBV-infected Li23/NTCP-myc Parent, A7, or A8 cells. The 
supernatant of HepG2.2.15 was used as HBVcc. Each mRNA level was calculated 
relative to the level in mock-infected cells, which was set at 1. (D) Proposed models of 
the cGAS-STING signaling pathways triggered by HBV. 
 
Supporting material 
Fig. S1. The subcloned cell lines of Li23/NTCP-myc cells, in which the cGAS 
expression was at the same low level as in A8 cells, also showed higher permissiveness 
to HBV infection than that in the parental cells. (A) Quantitative RT-PCR analysis of 
cGAS mRNAs in Li23/NTCP-myc cells (Parent), and their subcloned A8, B34, or B48 
cells. Each mRNA level was calculated relative to the level in parental Li23/NTCP-myc 
cells, which was assigned a value of 100%. (B) Quantitative RT-PCR analysis of the 
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total amount of HBV transcript in HBV-infected Li23/NTCP-myc Parent, A8, B34, or 
B48 cells. HBVcc were used as described in Fig. 4E. Total RNA extracted from the cells 
was subjected to quantitative RT-PCR analysis. 
